Скачать или смотреть Laurus Labs Q2FY26 Results | 886% Profit Jump | Dr. Satyanarayana Chava Interview Highlights

Laurus Labs has reported a blockbuster Q2FY26 with an 886% YoY profit jump and strong revenue growth across all segments — led by its CDMO business.
In this NDTV Profit interview, Dr. Satyanarayana Chava (CEO) shares insights on sustainable margins, expansion plans, and long-term profitability.
📊 Key Highlights:
Q2FY26 Revenue up 35% YoY to ₹1,653 crore
EBITDA doubled (₹403 crore) with 24.4% margin
PAT surged 886% to ₹195 crore
Operating cash flow crossed ₹1,000 crore in H1FY26
Focus on CDMO, Human Health & Animal Health
FY29 target: 20–25% ROCE through disciplined growth
💬 Dr. Chava also discussed Laurus’s strategic positioning under the Biosecure Act, sustainable capex from internal accruals, and bullish medium-term outlook.

Laurus Labs Q2FY26 Results, Laurus Labs Dr Satyanarayana Chava Interview, Laurus Labs CDMO Growth, Laurus Labs Profit 886%, Laurus Labs FY27 Outlook, Laurus Labs News, NDTV Profit Interview, Laurus Labs FY26 Earnings, CDMO Companies India, Pharma Stocks India 2025